Making malaria-treatment policy in the face of drug resistance.
about
Drug targets and mechanisms of resistance in the anaerobic protozoaHow sulfadoxine-pyrimethamine (SP) was perceived in some rural communities after phasing out chloroquine (CQ) as a first-line drug for uncomplicated malaria in Tanzania: lessons to learn towards moving from monotherapy to fixed combination therapyA retrospective analysis of the change in anti-malarial treatment policy: PeruCorrect dosing of artemether-lumefantrine for management of uncomplicated malaria in rural Tanzania: do facility and patient characteristics matter?Using evidence to change antimalarial drug policy in Kenya.Relationship between chloroquine toxicity and iron acquisition in Saccharomyces cerevisiae.Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial.Increasing antimalarial drug resistance in Uganda and revision of the national drug policy.From chloroquine to artemisinin-based combination therapy: the Sudanese experience.Multivariate evaluation of the effectiveness of treatment efficacy of cypermethrin against sea lice (Lepeophtheirus salmonis) in Atlantic salmon (Salmo salar).Population, behavioural and environmental drivers of malaria prevalence in the Democratic Republic of Congo.Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa.Consumers stated and revealed preferences for community health workers and other strategies for the provision of timely and appropriate treatment of malaria in southeast Nigeria.History, dynamics, and public health importance of malaria parasite resistance.Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania.Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugsThe implementation of a new Malaria Treatment Protocol in Timor-Leste: challenges and constraints.The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural TanzaniaAntimalarial drug resistance: a review of the biology and strategies to delay emergence and spreadChanging the malaria treatment protocol policy in Timor-Leste: an examination of context, process, and actors' involvementMalaria research and its influence on anti-malarial drug policy in Malawi: a case study.Chloroquine resistance before and after its withdrawal in Kenya.A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire.Amodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes.In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up.The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania.Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.Retail supply of malaria-related drugs in rural Tanzania: risks and opportunities.Controlling malaria: challenges and solutions.Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria.Adoption of the new antimalarial drug policy in Tanzania--a cross-sectional study in the community.Assessing the efficacy of chloroquine and sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in the Democratic Republic of Congo.The rationale and plan for creating a World Antimalarial Resistance Network (WARN).Sulphadoxine/pyrimethamine: an appropriate first-line alternative for the treatment of uncomplicated falciparum malaria in Ghanaian children under 5 years of age.In vitro antiplasmodial activity of ethanolic extracts of seaweed macroalgae against Plasmodium falciparum.Efficacies of mefloquine alone and of artesunate followed by mefloquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.Beyond evidence: a retrospective study of factors influencing a malaria treatment policy change in two South African provinces
P2860
Q24550694-4000155B-591E-4928-AFA5-279E901713ABQ25255530-8AFBFC17-F559-4086-B005-720F45D8CCE3Q30487719-C7597D96-4CC0-40CE-972A-D563231CD481Q33645108-737C4D89-5EA5-484A-A173-9B05C308A4CAQ34109430-BCF223E0-74CA-4933-B8D9-A1EA6A3C1F23Q34113689-601842F2-40D0-4D31-82BF-696F8E4EE7F1Q34666104-D3DEE60F-9B2C-411B-B054-6692C44A8BD8Q35013414-619806C9-1BF0-4AD5-84F8-6A45D13F1B8BQ35065971-C551D516-8D4C-4912-BB79-315144BF1980Q35071976-048BF143-46F9-4CA0-98B9-B264E503B07DQ35136234-F0E17EED-74BE-4B86-A708-A3CAA5907A8AQ35147242-3F0ABEA0-5CAD-47AE-ACEB-F4AA83394AF9Q35222336-156D37F4-2DC6-438A-BD79-801A5B11297DQ35545447-29DB37C1-2487-4BEA-8C51-15E33E2DCF74Q35727781-72C70805-0485-400C-B1D3-C2ED7C48F63FQ35838600-4C170A47-3ED2-4A59-B115-8E6BD81F1308Q36314347-DE03D9BB-8F71-46C7-A0D9-04F7F651CB61Q36443296-094A5454-8053-4A9A-91D7-AAB8672BE70AQ36473618-733DEE72-AAF6-4506-93B5-42654320A003Q36722524-86AED52C-AC67-47F9-AAA1-A873ADC1B316Q36880704-25613434-C537-4B5D-8D54-65855CB0D95CQ36955257-3E9ADFCE-271D-4CAC-A68A-24F4BC024BCEQ37223629-B6B60549-22E4-43CA-8391-DDCD6F175AA5Q37271800-1117C7D7-6966-4ADE-A6E1-7E735416960EQ37423034-80D263FE-1773-4FD3-ABE2-DD738BD2DA49Q37598657-5A7FCC53-BE01-4E11-9BF4-8F4189D83950Q38453822-6367F835-B9BB-4F39-AE5F-14BFE1B17CF4Q38882145-FD99C7A5-3B3E-418C-9D5C-39A0FF098390Q39028582-29D89F36-7ED3-41F4-98CB-2726B7EFDDC5Q39322857-E991E95F-968C-46F2-A1F2-4157A69F7C4FQ39468706-77B37AEF-D8C9-4D9F-8280-F98FD92C2AB3Q40497923-E3360256-90D6-4628-B540-FDC0B64D2071Q40559239-99CBE04D-9639-4CF0-B72B-22321EB5BEF5Q41540119-A49441B1-3C5C-48A5-8166-0E7033E4ABA4Q41917325-8F41E121-F2A8-47C3-BD1B-2FD5271A83B9Q41934325-09A0DD67-13F8-4798-BAF7-E9BD6F15F414Q46425189-532082D6-E5F4-4A00-B8D2-2513F290002BQ57230537-AAA379EB-CA4B-4EAF-9F5B-E3F6A226C639
P2860
Making malaria-treatment policy in the face of drug resistance.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Making malaria-treatment policy in the face of drug resistance.
@ast
Making malaria-treatment policy in the face of drug resistance.
@en
type
label
Making malaria-treatment policy in the face of drug resistance.
@ast
Making malaria-treatment policy in the face of drug resistance.
@en
prefLabel
Making malaria-treatment policy in the face of drug resistance.
@ast
Making malaria-treatment policy in the face of drug resistance.
@en
P356
P1476
Making malaria-treatment policy in the face of drug resistance.
@en
P2093
P356
10.1080/00034989958753
P577
1999-01-01T00:00:00Z